PL1871368T3 - Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji - Google Patents

Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji

Info

Publication number: PL1871368T3
Authority: PL; Poland
Prior art keywords: therapeutically effective; effective amounts; disease; dementia; dihydropyridine compounds
Prior art date: 2005-04-04

Application number

PL06740387T

Other languages

English (en)

Inventor

Julian A Gray

Yamanishi Yoshiharu

Mori Nobuyuki

Scott Fields

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-04

Filing date

2006-04-04

Publication date

2011-12-30

2006-04-04 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2011-12-30 Publication of PL1871368T3 publication Critical patent/PL1871368T3/pl

Links

208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
206010012289 Dementia Diseases 0.000 title abstract 2
230000004770 neurodegeneration Effects 0.000 title abstract 2
125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 title 1
MMWRGWQTAMNAFC-UHFFFAOYSA-N 1,2-Dihydropyridine Natural products C1NC=CC=C1 MMWRGWQTAMNAFC-UHFFFAOYSA-N 0.000 abstract 3
-1 1,2-dihydropyridine compounds Chemical class 0.000 abstract 3
239000000544 cholinesterase inhibitor Substances 0.000 abstract 3
229940098747 AMPA receptor antagonist Drugs 0.000 abstract 2
239000000775 AMPA receptor antagonist Substances 0.000 abstract 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
239000002664 nootropic agent Substances 0.000 abstract 2
230000001777 nootropic effect Effects 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
229940122041 Cholinesterase inhibitor Drugs 0.000 abstract 1
208000028698 Cognitive impairment Diseases 0.000 abstract 1
208000023105 Huntington disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
229960003530 donepezil Drugs 0.000 abstract 1
PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

PL06740387T 2005-04-04 2006-04-04 Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji PL1871368T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US66766505P	2005-04-04	2005-04-04
US68951905P	2005-06-13	2005-06-13
EP06740387A EP1871368B1 (en)	2005-04-04	2006-04-04	Dihydropyridine compounds for neurodegenerative diseases and dementia
PCT/US2006/012284 WO2006107859A2 (en)	2005-04-04	2006-04-04	Dihydropyridine compounds for neurodegenerative diseases and dementia

Publications (1)

Publication Number	Publication Date
PL1871368T3 true PL1871368T3 (pl)	2011-12-30

Family

ID=37074003

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL06740387T PL1871368T3 (pl)	2005-04-04	2006-04-04	Związki dihydropirydynowe do zastosowania w chorobach neurodegeneracyjnych i demencji

Country Status (16)

Country	Link
US (3)	US20060270709A1 (pl)
EP (2)	EP1871369A4 (pl)
JP (2)	JP5180816B2 (pl)
KR (1)	KR20080007233A (pl)
AT (1)	ATE511843T1 (pl)
AU (1)	AU2006232517A1 (pl)
CA (1)	CA2603258A1 (pl)
CY (1)	CY1112427T1 (pl)
DK (1)	DK1871368T3 (pl)
HR (1)	HRP20110524T1 (pl)
IL (1)	IL186412A0 (pl)
ME (1)	ME01224B (pl)
PL (1)	PL1871368T3 (pl)
PT (1)	PT1871368E (pl)
RS (1)	RS51822B (pl)
WO (2)	WO2006107859A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005047256A1 (fr) *	2003-11-14	2005-05-26	Shanghai Genomics, Inc.	Derives de pyridone, et utilisation correspondante
ME01224B (me) *	2005-04-04	2013-06-20	Eisai R&D Man Co Ltd	Jedinjenja dihidropiridina za liječenje neurodegenerativnih bolesti i demencije
CA2603959A1 (en) *	2005-04-08	2006-10-19	Eisai R & D Management Co., Ltd.	Therapeutic agent for dyskinesia
SI1928454T1 (sl)	2005-05-10	2015-01-30	Intermune, Inc.	Piridonski derivati za moduliranje s stresom aktiviranega protein kinaznega sistema
US7718807B2 (en) *	2006-04-28	2010-05-18	Eisai R&D Management Co., Ltd.	Salt of 1,2-dihydropyridine compound
KR20090087009A (ko) *	2006-10-27	2009-08-14	메디베이션 뉴롤로지 인코퍼레이티드	아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
CA2677096A1 (en)	2007-01-31	2008-08-07	Vertex Pharmaceuticals Incorporated	Kinase inhibitors
US20100099714A1 (en) *	2007-03-05	2010-04-22	Eisai R&D Management Co., Ltd.	AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
WO2009011412A2 (en) *	2007-07-13	2009-01-22	Eisai R & D Management Co., Ltd.	Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
WO2009054543A1 (en) *	2007-10-26	2009-04-30	Eisai R & D Management Co., Ltd.	Ampa receptor antagonists and zonisamide for parkinson's disease and movement disorders
EP2254577A1 (en) *	2007-12-26	2010-12-01	Eisai R&D Management Co., Ltd.	Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US20090221554A1 (en) *	2008-02-28	2009-09-03	Zenyaku Kogyo Kabushiki Kaisha	Method of treating cognitive impairment
US8598150B1 (en)	2008-04-02	2013-12-03	Jonathan R. Brestoff	Composition and method for affecting obesity and related conditions
US8987245B2 (en)	2008-04-02	2015-03-24	Jonathan R. Brestoff Parker	Composition and method for affecting obesity and related conditions
CA3034994A1 (en)	2008-06-03	2009-12-10	Intermune, Inc.	Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
CA2731451A1 (en)	2008-07-23	2010-01-28	Vertex Pharmaceuticals Incorporated	Pyrazolopyridine kinase inhibitors
US8569337B2 (en)	2008-07-23	2013-10-29	Vertex Pharmaceuticals Incorporated	Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000837A (es)	2008-07-23	2011-04-05	Vertex Pharma	Inhibidores de pirazolpiridina cinasa triciclica.
AU2009279611A1 (en) *	2008-08-06	2010-02-11	Vertex Pharmaceuticals Incorporated	Aminopyridine kinase inhibitors
KR101381074B1 (ko)	2008-12-23	2014-04-11	에프. 호프만-라 로슈 아게	Ｐ2ｘ7 조절제로서의 디히드로피리돈 아미드
US8153808B2 (en)	2008-12-23	2012-04-10	Roche Palo Alto Llc	Dihydropyridone amides as P2X7 modulators
EP2382202A1 (en)	2008-12-23	2011-11-02	F. Hoffmann-La Roche AG	Dihydropyridone amides as p2x7 modulators
EP2391604A1 (en)	2008-12-23	2011-12-07	F. Hoffmann-La Roche AG	Dihydropyridone amides as p2x7 modulators
CA2745866A1 (en)	2008-12-23	2010-07-01	F.Hoffmann-La Roche Ag	Dihydropyridone ureas as p2x7 modulators
AU2010245914A1 (en)	2009-05-06	2011-12-15	Vertex Pharmaceuticals Incorporated	Pyrazolopyridines
WO2011094290A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyrimidine kinase inhibitors
CA2787079A1 (en)	2010-01-27	2011-08-04	Vertex Pharmaceuticals Incorporated	Pyrazolopyrazine kinase inhibitors
CN102858769A (zh)	2010-01-27	2013-01-02	沃泰克斯药物股份有限公司	吡唑并吡啶激酶抑制剂
JO2998B1 (ar)	2010-06-04	2016-09-05	Amgen Inc	مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
JP6093770B2 (ja)	2011-09-27	2017-03-08	アムジエン・インコーポレーテツド	癌の治療のためのｍｄｍ２阻害剤としての複素環化合物
US8722060B2 (en) *	2012-05-23	2014-05-13	William J. Binder	Method of treating vertigo
WO2013137969A1 (en)	2012-03-12	2013-09-19	Binder William J	Treatment of migraine headaches with presynaptic neurotoxin
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
TW201441193A (zh)	2012-12-06	2014-11-01	Kyowa Hakko Kirin Co Ltd	吡啶酮化合物
US11407721B2 (en)	2013-02-19	2022-08-09	Amgen Inc.	CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
MX368703B (es)	2013-02-28	2019-10-11	Amgen Inc	Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
CA2906538C (en)	2013-03-14	2021-02-02	Ana Gonzalez Buenrostro	Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar)	2013-06-10	2017-06-16	Amgen Inc	عمليات صنع وأشكال بلورية من mdm2 مثبط
RU2692485C2 (ru)	2014-04-02	2019-06-25	Интермьюн, Инк.	Противофиброзные пиридиноны
CA2971872C (en)	2014-12-22	2023-10-10	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Mutant idh1 inhibitors useful for treating cancer
SG11201809297UA (en) *	2016-04-26	2018-11-29	H Lundbeck As	Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
US11364225B2 (en) *	2019-08-21	2022-06-21	Bn Intellectual Properties, Inc.	Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
EP4403185A1 (en) *	2021-09-15	2024-07-24	University of The Ryukyus	Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
EP4403184A1 (en) *	2021-09-15	2024-07-24	University of The Ryukyus	Pharmaceutical composition for use in treating cognitive decline, excess weight, or obesity
US11878958B2 (en)	2022-05-25	2024-01-23	Ikena Oncology, Inc.	MEK inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI95572C (fi) *	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5262165A (en)	1992-02-04	1993-11-16	Schering Corporation	Transdermal nitroglycerin patch with penetration enhancers
JP3075566B2 (ja)	1990-05-15	2000-08-14	エーザイ株式会社	光学活性インダノン誘導体
JP2965675B2 (ja)	1990-11-21	1999-10-18	エーザイ株式会社	（―）―１―ベンジル―４―〔（５，６―ジメトキシ―１―インダノン）―２―イル〕メチルピペリジンの製造方法
US6010715A (en)	1992-04-01	2000-01-04	Bertek, Inc.	Transdermal patch incorporating a polymer film incorporated with an active agent
US5843945A (en)	1993-05-13	1998-12-01	Neurosearch A/S	AMPA antagonists and a method of treatment
DE4428835A1 (de) *	1994-08-01	1996-02-08	Schering Ag	Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
CA2199468C (en) *	1994-09-27	2006-06-06	Jun-Ichi Shishikura	1,2,3,4-tetrahydroquinoxalinedione derivative
JP3534775B2 (ja)	1995-06-07	2004-06-07	オーソ―マクニールファーマシューティカル，インコーポレイテッド	１７−デアセチルノルゲスチマートを単独でまたはエストロゲンと組み合わせて投与するための経皮パッチおよび方法
TW513409B (en) *	1996-06-07	2002-12-11	Eisai Co Ltd	Polymorphs of donepezil hydrochloride
WO1997046526A1 (en) *	1996-06-07	1997-12-11	Eisai Co., Ltd.	Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
RU2181362C2 (ru) *	1996-10-24	2002-04-20	Новартис Аг	Производные аминофосфоновых и -фосфиновых кислот, способ их получения и фармацевтические составы на их основе
WO1998039000A1 (en) *	1997-03-03	1998-09-11	Eisai Co., Ltd.	Use of cholinesterase inhibitors to treat disorders of attention
US6060479A (en) *	1997-06-09	2000-05-09	Pfizer Inc	Quinazoline-4-one AMPA antagonists
US5948433A (en)	1997-08-21	1999-09-07	Bertek, Inc.	Transdermal patch
DK1048653T3 (da) *	1997-12-05	2004-05-24	Eisai Co Ltd	Donepezilpolykrystaller og fremgangsmåde til fremstilling deraf
JP2002505288A (ja)	1998-03-02	2002-02-19	コセンシス，インコーポレイテッド	置換キナゾリンおよびアナログならびにそれらの使用
IT1304904B1 (it) *	1998-09-11	2001-04-05	Eisai Co Ltd	Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
FR2805260A1 (fr) *	2000-02-18	2001-08-24	Adir	Nouveaux derives d'acides 6-sulfamoyl-3-quinolinyl phosphoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20060183776A9 (en) *	2000-03-03	2006-08-17	Eisai Co., Ltd.	Liquid dosage formulations of donepezil
EP2133078A1 (en) *	2000-03-03	2009-12-16	Eisai R&D Management Co., Ltd.	Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments
US20030153598A1 (en) *	2000-07-25	2003-08-14	Raymond Pratt	Methods for treating Parkinson's disease with cholinesterase inhibitors
US20030144255A1 (en) *	2000-03-06	2003-07-31	Bain Allen I	Compositions for prevention and treatment of dementia
ATE420862T1 (de) *	2000-06-12	2009-01-15	Eisai R&D Man Co Ltd	1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
JP2002047272A (ja) *	2000-07-26	2002-02-12	Dai Ichi Seiyaku Co Ltd	ポリアミンアミド誘導体
CA2422589C (en) *	2000-09-18	2011-08-09	Eisai Co., Ltd.	Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
WO2003024456A1 (en) *	2001-09-20	2003-03-27	Eisai Co., Ltd.	Methods for treating and preventing migraines
GB0129260D0 (en) *	2001-12-06	2002-01-23	Eisai London Res Lab Ltd	Pharmaceutical compositions and their uses
WO2004034963A2 (en) *	2002-05-17	2004-04-29	Eisai Co., Ltd.	Methods and compositions using cholinesterase inhibitors
JP4208512B2 (ja) *	2002-07-23	2009-01-14	株式会社クラレ	５−（２’−ピリジル）−２−ピリドン誘導体の製造方法
JP2004189706A (ja) *	2002-12-13	2004-07-08	Eisai Co Ltd	高度アルツハイマー型痴呆治療剤
MY148809A (en) *	2004-07-06	2013-05-31	Eisai R&D Man Co Ltd	Crystals of 1,2-dihydropyridine compound and their production process
ME01224B (me) *	2005-04-04	2013-06-20	Eisai R&D Man Co Ltd	Jedinjenja dihidropiridina za liječenje neurodegenerativnih bolesti i demencije

2006
- 2006-04-04 ME MEP-2011-133A patent/ME01224B/me unknown
- 2006-04-04 US US11/396,555 patent/US20060270709A1/en not_active Abandoned
- 2006-04-04 PL PL06740387T patent/PL1871368T3/pl unknown
- 2006-04-04 US US11/887,729 patent/US20090131480A1/en not_active Abandoned
- 2006-04-04 CA CA002603258A patent/CA2603258A1/en not_active Abandoned
- 2006-04-04 JP JP2008505417A patent/JP5180816B2/ja not_active Expired - Fee Related
- 2006-04-04 RS RS20110318A patent/RS51822B/en unknown
- 2006-04-04 DK DK06740387.3T patent/DK1871368T3/da active
- 2006-04-04 WO PCT/US2006/012284 patent/WO2006107859A2/en active Application Filing
- 2006-04-04 EP EP06749149A patent/EP1871369A4/en not_active Withdrawn
- 2006-04-04 US US11/396,621 patent/US20060276510A1/en not_active Abandoned
- 2006-04-04 AT AT06740387T patent/ATE511843T1/de active
- 2006-04-04 JP JP2008505418A patent/JP2008537552A/ja not_active Withdrawn
- 2006-04-04 KR KR1020077025426A patent/KR20080007233A/ko not_active Ceased
- 2006-04-04 EP EP06740387A patent/EP1871368B1/en active Active
- 2006-04-04 AU AU2006232517A patent/AU2006232517A1/en not_active Abandoned
- 2006-04-04 WO PCT/US2006/012285 patent/WO2006107860A2/en active Application Filing
- 2006-04-04 PT PT06740387T patent/PT1871368E/pt unknown
2007
- 2007-10-07 IL IL186412A patent/IL186412A0/en unknown
2011
- 2011-07-12 HR HR20110524T patent/HRP20110524T1/hr unknown
- 2011-07-29 CY CY20111101013T patent/CY1112427T1/el unknown

Also Published As

Publication number	Publication date
JP2008537552A (ja)	2008-09-18
US20060276510A1 (en)	2006-12-07
EP1871369A4 (en)	2009-11-11
WO2006107859A2 (en)	2006-10-12
JP2008538216A (ja)	2008-10-16
PT1871368E (pt)	2011-08-30
US20060270709A1 (en)	2006-11-30
AU2006232517A1 (en)	2006-10-12
US20090131480A1 (en)	2009-05-21
RS51822B (en)	2012-02-29
JP5180816B2 (ja)	2013-04-10
WO2006107859A3 (en)	2009-04-09
EP1871369A2 (en)	2008-01-02
HRP20110524T1 (hr)	2011-08-31
EP1871368B1 (en)	2011-06-08
EP1871368A2 (en)	2008-01-02
CA2603258A1 (en)	2006-10-12
CY1112427T1 (el)	2015-12-09
DK1871368T3 (da)	2011-09-19
ATE511843T1 (de)	2011-06-15
IL186412A0 (en)	2008-08-07
WO2006107860A3 (en)	2009-04-09
WO2006107859A8 (en)	2007-11-08
EP1871368A4 (en)	2009-11-11
ME01224B (me)	2013-06-20
WO2006107860A2 (en)	2006-10-12
KR20080007233A (ko)	2008-01-17

Publication	Publication Date	Title
EP1871368A4 (en)	2009-11-11	DIHYDROPYRIDINE COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES AND DEMENTIA
WO2008111590A3 (en)	2009-02-19	Ampa and nmda receptor antagonists for neurodegenerative diseases
WO2009011412A3 (en)	2009-05-07	Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
UA99620C2 (en)	2012-09-10	Pyridyl piperidine orexin receptor antagonists
MX2007002521A (es)	2007-05-09	Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
WO2007056219A3 (en)	2007-12-27	[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
NO20060328L (no)	2006-02-17	Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
DE60224404D1 (de)	2008-02-14	Substiuierte piperidine als melanocortinrezeptor-modulatoren
MXPA05010496A (es)	2005-11-16	Moduladores alostericos positivos del receptor de acetilcolina nicotinico.
WO2007079214A3 (en)	2007-08-30	Prokineticin 2 receptor antagonists
MA28706B1 (fr)	2007-06-01	Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
MX346186B (es)	2017-03-10	Inhibidores de proteina cinasas.
MX2010001486A (es)	2010-03-01	Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
HRP20050774A2 (en)	2006-09-30	Imidazol-4-yl-ethylnyl-pyridine derivatives
TN2009000452A1 (en)	2011-03-31	[4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2007092861A3 (en)	2008-03-20	Inhibitors specific of presenilin-1 and their uses
TW200732304A (en)	2007-09-01	Piperidine derivatives
MX2009006528A (es)	2009-06-26	Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
MX2009011416A (es)	2009-11-05	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
MXPA05012900A (es)	2006-02-22	Derivados de pirrol sustituidos.
WO2008014247A3 (en)	2008-03-20	4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
TW200628476A (en)	2006-08-16	Azabenzoxazoles for the treatment of CNS disorders
MX2024000903A (es)	2024-02-06	Formas cristalinas.
WO2006135545A3 (en)	2007-08-02	A method for the prevention and/or treatment of neurodegenerative diseases characterized by administering an ep1 receptor antagonist